CardioLogical Solutions Receives an Additional Patent for its Aortic Embolic Protection Devices Designed to Prevent Stroke and Other Ischemic Complications
LOS ALTOS, Calif.--(BUSINESS WIRE)--Jan 14, 2013--CardioLogical Solutions, an emerging cardiovascular device company formed by the recent merger of Emboline and VasoStitch, announced today that it has been issued an additional patent for its family of aortic embolic protection devices that are designed to prevent stroke and other ischemic complications.
The aortic embolic protection technologies of Emboline and the large-hole access and closure technologies of VasoStitch form the initial core of a suite of accessory devices offered by CardioLogical Solutions to address the clinical needs of emerging interventional cardiology procedures. Added to these is a novel approach to preventing contrast nephropathy during cardiovascular procedures. The technologies of CardioLogical Solutions are derived from intellectual property invented by serial entrepreneur Amir Belson, M.D., founder of NeoGuide Systems, Vascular Pathways, Zipline Medical, Thermocure and Radguard Medical.
“This new issued patent affords CardioLogical Solutions additional IP protection for the most comprehensive range of accessory products aimed at the TAVR community today,” said David W. J. Smith, CEO. “Indeed, our three platforms of procedural accessory devices address the three most pressing clinical needs in the rapidly growing evolution of transcatheter aortic valve replacement (TAVR) therapies: specifically, (1) a dire need for nonsurgical, large-hole (>12 Fr) access and closure technologies, (2) aortic embolic protection devices for prevention of stroke and other ischemic complications, and (3) prevention of contrast nephropathy. The combined potential of these markets where there exists now a strong clinical need is estimated at $2 to $3 billion per year, and this is where CardioLogical Solutions is focused.” CardioLogical Solutions is currently in the advanced stages of raising a Series B preferred round to achieve CE mark for the initial Emboline and VasoStitch products, and proof-of-concept for its contrast nephropathy technology. First commercial sales are estimated in the ninth calendar quarter following close of funding, beginning with the European launch of the first VasoStitch product, followed by the European launch of the first Emboline device approximately six months later.
About CardioLogical Solutions Privately held CardioLogical Solutions is an emerging medical technology company focused on developing three novel accessory device platforms for interventional cardiology procedures. Specifically, the recent emergence of transcatheter aortic valve replacement (TAVR) therapies has created a critical need for (1) nonsurgical, large-hole (>12 Fr) access and closure technologies, (2) aortic embolic protection devices for prevention of stroke and other ischemic complications, and (3) prevention of contrast nephropathy. The combined potential for these three markets where there exists now a strong clinical need is estimated at $2 to 3 billion. CardioLogical Solutions was founded by serial entrepreneur Amir Belson, M.D.
NOTICE: CardioLogical Solutions’ products are not available for sale in the United States.CONTACT: Ronald Trahan Associates Inc.
Ronald Trahan, APR, 508-359-4005, x108 KEYWORD: UNITED STATES NORTH AMERICA CALIFORNIA INDUSTRY KEYWORD: HEALTH CARDIOLOGY MEDICAL DEVICES OTHER HEALTH SOURCE: CardioLogical Solutions Copyright Business Wire 2013 PUB: 01/14/2013 11:49 AM/DISC: 01/14/2013 11:49 AM http://www.businesswire.com/news/home/20130114006084/